Clinical Trials Logo

Perennial Allergic Rhinitis clinical trials

View clinical trials related to Perennial Allergic Rhinitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05299086 Recruiting - Child, Only Clinical Trials

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis

Start date: April 4, 2022
Phase: N/A
Study type: Interventional

Allergic rhinitis in children is common. According to the international study of asthma and allergies in childhood (ISAAC) phase III, the global prevalence of allergic rhinitis among children is increasing to 40.1% and the prevalence of allergic rhinitis in Bangkok area in 2018, among children aged 6-7 and 13-14 years was 16.32%. This disease is a global health problem affecting quality of life of patients in daily life, work, study and sleep. Intranasal corticosteroid is the most effective treatment for allergic rhinitis. From real world evidence; most of allergic rhinitis patient use the drug when symptoms worsen. In children, the use of intranasal corticosteroid may cause minor local side effects such as dryness, burning sensation or epistaxis. In some intranasal corticosteroid, long-term use may result in decreased growth compared to placebo which make parents concern. The investigators interested in studying the efficacy of intranasal corticosteroid comparing between daily use and as needed use in children with allergic rhinitis. To study the appropriate form of treatment to increase cooperation. Patient will have a better quality of life and reduce the risk of side effects from prolonged use of intranasal corticosteroid. From the literature review, it was found that most studies were conducted among adult patients with seasonal allergic rhinitis In Thailand in 2020, Thongngam et al. studied the efficacy of intranasal corticosteroid was compared between daily use and as needed use in adult patients with perennial allergic rhinitis. The results of the study concluded that the daily use group can reduced more TNSS (total nasal symptoms score) but was not statistically significant and had a greater increase in peak nasal inspiratory flow (PNIF) compared to as needed group. Interestingly, the quality of life assessment (RCQ-36 score) in both2 groups improved equally, In as needed group, the cumulative dose was 51% lower than the daily dose group. The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.

NCT ID: NCT04544774 Recruiting - Clinical trials for Seasonal Allergic Rhinitis

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy

Start date: July 16, 2020
Phase:
Study type: Observational [Patient Registry]

This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy. The NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years. This study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine / Allergology

NCT ID: NCT03009136 Recruiting - Clinical trials for Perennial Allergic Rhinitis

Efficacy and Safety of So-Cheong-Ryong-Tang on Perennial Allergic Rhinitis

Start date: December 31, 2016
Phase: Phase 3
Study type: Interventional

The aim of this study is to investigate the short and long term efficacy and the safety of SCRT treatment for PAR